Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come

Executive Summary

Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.
Advertisement

Related Content

Express Scripts Planning Active Role In Insurance Exchanges
Despite Specialty Rx Growth, Overall Medicare Drug Spend Rose Only 1.3% Per Member Per Month – Express Scripts
Despite Specialty Rx Growth, Overall Medicare Drug Spend Rose Only 1.3% Per Member Per Month – Express Scripts
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
As Yervoy Launch Nears, Pricing Of Maintenance Therapy Remains A Key Question
Companion Diagnostics: A Business Area Fraught With Challenges Ahead
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
For NMEs, The Song Remains The Same: Specialty Markets Eye Further Growth For 2010, While Traditional Big Pharma, Primary Care NDAs Are Few
For NMEs, The Song Remains The Same: Specialty Markets Eye Further Growth For 2010, While Traditional Big Pharma, Primary Care NDAs Are Few

Topics

Advertisement
UsernamePublicRestriction

Register

PS053350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel